Prostatic Neoplasms

Bertaccini A, Fandella A, Prayer-Galetti T, Scattoni V, Galosi AB, Ficarra V, Trombetta C, Gion M, Martorana G, Anonymous00176. · Department of Urology, Alma Mater Studiorum University of Bologna, Sant'Orsola-Malpighi Hospital, Palagi Str. 9, 40100, Bologna, Italy. · Anticancer Res. · Pubmed #17348457 No free full text.

Abstract: BACKGROUND: The only available method to detect prostate cancer is prostate biopsy; however, to our knowledge, no evidence-based clinical practice guidelines have been established on this topic. MATERIALS AND METHODS: A three-year project was elaborated in which experts in the field worked to define the controversies existing in clinical practice regarding prostatic biopsies and then to develop guidelines by means of a systematic search of all the English-language literature using online databases and a consensus conference. RESULTS AND CONCLUSION: The guidelines were formulated to help practitioners in making clinical decisions regarding the appropriate time the patient should undergo prostate biopsy, the type of antibiotic prophylaxis and anaesthesia, the biopsy approach, the method for processing and reporting prostatic needle cores, the biopsy technique, when to repeat a biopsy after a prior negative biopsy, radiotherapy or radical prostatectomy and the accuracy of biopsies in staging prostate cancer.

Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A, Venselaar J, Hoskin P, Anonymous00119. · Department of Radiation Oncology, Europe Hospitals, Brussels, Belgium. · Radiother Oncol. · Pubmed #17321620 No free full text.

Abstract: The aim of this paper is to supplement the GEC/ESTRO/EAU recommendations for permanent seed implantations in prostate cancer to develop consistency in target and volume definition for permanent seed prostate brachytherapy. Recommendations on target and organ at risk (OAR) definitions and dosimetry parameters to be reported on post implant planning are given.

Bourguet P, Planchamp F, Montravers F, Vincendeau S, Courbon F, Edeline V, Helal BO, Rossi D, Villers A, Anonymous00504, Anonymous00505, Anonymous00506, Anonymous00507, Anonymous00508, Anonymous00509, Anonymous00510, Anonymous00511. · Centre Eugène-Marquis, Rennes. · Bull Cancer. · Pubmed #17191352 links to  free full text

This publication has no abstract.

Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG, Anonymous00097. · No affiliation provided · J Natl Compr Canc Netw. · Pubmed #17112448 No free full text.

This publication has no abstract.

Boehmer D, Maingon P, Poortmans P, Baron MH, Miralbell R, Remouchamps V, Scrase C, Bossi A, Bolla M, Anonymous00259. · Klinik f. Strahlentherapie, Universitätsmedizin Berlin, Charité Campus Mitte, Germany. · Radiother Oncol. · Pubmed #16797094 No free full text.

Abstract: BACKGROUND AND PURPOSES: The appropriate application of 3-D conformal radiotherapy, intensity modulated radiotherapy or image guided radiotherapy for patients undergoing radiotherapy for prostate cancer requires a standardisation of target delineation as well as clinical quality assurance procedures. PATIENTS AND METHODS: Pathological and imaging studies provide valuable information on tumour extension. In addition, clinical investigations on patient positioning and immobilisation as well as treatment verification data offer an abundance of information. RESULTS: Target volume definitions for different risk groups of prostate cancer patients based on pathological and imaging studies are provided. Available imaging modalities, patient positioning and treatment preparation studies as well as verification procedures are collected from literature studies. These studies are summarised and recommendations are given where appropriate. CONCLUSIONS: On behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Radiation Oncology Group this article presents a common set of recommendations for external beam radiotherapy of patients with prostate cancer.

Miller K, Becker K, Finke F, Geiges G, Göckel-Beining B, Hossfeld DK, Miller K, Osieka R, Rüssel C, Tesch H, Weissbach L, Wirth M, Wolff JM. · Charité - Campus Benjamin Franklin, Universitätsmedizin, Berlin. · Aktuelle Urol. · Pubmed #16733822 No free full text.

Abstract: Therapy with Docetaxel for hormone-refractory prostatic carcinoma has for the first time led to an increase in the survival time. Docetaxel has become established as a standard therapy for his indication. Since hormone-refractory prostatic carcinoma is not uniformly defined and is thus for prognosis not a homogeneous entity, the prospects at the start of chemotherapy are uncertain. In the summer of 2005 these questions were addressed in an interdisciplinary consensus conference. It was agreed that the 3-week scheme with 75 mg/m (2) as standard and the indication for symptomatic patients were above question. Opinions differed with regard to the use of chemotherapy in asymptomatic patients. In addition, recommendations for the performance and monitoring of the therapy were formulated.

Maceira Rozas Mdel C, Rey Liste T, García Caeiro AL, García Comesaña J. · Axencia de Avaliación de Tecnoloxías Sanitarias de Galicia, avalia-t. Consellería de Sanidade, Xunta de Galicia. · Clin Transl Oncol. · Pubmed #16648101 No free full text.

Abstract: Intensity-modulated radiation therapy (IMRT) is an advanced form of radiotherapy for the treatment of cancer that allows, on one hand, to administer a more homogeneous dose to the patients on the volume to irradiate (which would increase the local control of the disease), and on the other hand, to diminish the toxicity in the organs at risk. This type of treatment is based on imaging techniques, on computer dosimetry programs, and on more precise immobilization accessories. Before delivering IMRT it is necessary to establish a protocol that includes the different phases of the treatment process, that is, the obtaining of anatomical data, beam definition, calculation, dose distribution, and treatment performance and control. In this article we present the basic standards for the IMRT treatment for prostate and head-neck cancer agreed upon a consensus meeting. The follow-up of the recommendations settled down in this document will help in the establishment of a standardized clinical practice -assuring the quality- and a better evaluation of the results of the clinical intervention.

Richaud P, Moreau JL, Beuzeboc P, Rébillard X, Villers A, Peyromaure M, Cornud F, Soulié M, Davin JL, Anonymous00194. · Comité Prostate du CCAFU. · Prog Urol. · Pubmed #16459666 No free full text.

Abstract: The follow-up of prostate cancer is especially justified now that effective treatment options are available in the case of recurrence. Conditions of follow-up of patients with prostate cancer vary according to age, comorbidities, tumour stage, prognostic factors at diagnosis and the pervious treatment sequence.

Bianchi G, Bracarda S, Bruzi P, Bufo P, Celesti R, De Maria M, Gallucci M, Gelmini A, Guidi G, Manente P, Rusticali B, Tombesi M, Viafora C, Zorat P, Anonymous00056. · Società Italiana di Urologia. · Arch Ital Urol Androl. · Pubmed #16402733 No free full text.

This publication has no abstract.

De Luca S, Bertaccini A, Galetti TP, Anonymous00055. · U.O. di Urologia, Ospedale Gradenigo, Torino. · Arch Ital Urol Androl. · Pubmed #16402732 No free full text.

This publication has no abstract.

Bertè R, Anonymous00054. · U.O. Urologia, Ospedale Civile di Gorizia. · Arch Ital Urol Androl. · Pubmed #16402731 No free full text.

This publication has no abstract.

Bortolus R, Anonymous00053. · Oncologia Radioterapica, Centro Riferimento Oncologico, Aviano (PN). · Arch Ital Urol Androl. · Pubmed #16402730 No free full text.

This publication has no abstract.

Fandella A, Bertaccini A, Consonni P, Introini C, Gunelli R, Anonymous00052. · U.O. di Urologia, Ospedale Regionale, Treviso. · Arch Ital Urol Androl. · Pubmed #16402729 No free full text.

This publication has no abstract.

Galosi AB, Maruzzi D, Milani C, Nava L, Scattoni V, Zambolin T, Anonymous00051. · Clinica Urologica, Ospedale Torrette, Università di Ancona. · Arch Ital Urol Androl. · Pubmed #16402728 No free full text.

This publication has no abstract.

De Matteis A, Bollito E, Galosi AB, Gardiman M, Montironi R, Sentinelli S, Anonymous00050. · Dip. Med. Sper. e Patologia, Universita La Sapienza, Roma. · Arch Ital Urol Androl. · Pubmed #16402727 No free full text.

This publication has no abstract.

Bertaccini A, Consonni P, Schiavina R, Virgili G, Randone D, D'Incà G, Muzzonigro G, Anonymous00049. · Clinica Urologica, Policlinico S. Orsola-Malpighi, Bologna. · Arch Ital Urol Androl. · Pubmed #16402726 No free full text.

This publication has no abstract.

Ferrante GL, Manferrari F, Maruzzi D, Anonymous00048. · U.O. di Urologia, Ospedale Regionale di Treviso. · Arch Ital Urol Androl. · Pubmed #16402725 No free full text.

This publication has no abstract.

Prayer-Galetti T, Ficarra V, Franceschini R, Liguori G, Martino P, Schiavina R, Anonymous00047. · Clinica Urologica, Università di Padova. · Arch Ital Urol Androl. · Pubmed #16402724 No free full text.

This publication has no abstract.

Anonymous00131. · No affiliation provided · Actas Urol Esp. · Pubmed #16353767 links to  free full text

This publication has no abstract.

Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F, Anonymous00098. · No affiliation provided · Eur Urol. · Pubmed #16046052 No free full text.

Abstract: OBJECTIVES: The first summary of the European Association of Urology (EAU) guidelines on prostate cancer was published in 2001. These guidelines have been continuously updated since many important changes affecting the clinical management of patients with prostate cancer have occurred over the past years. The aim of this paper is to present a summary of the 2005 update of the EAU guidelines on prostate cancer. METHODS: A literature review of the new data has been performed by the working panel. The guidelines have been updated and level of evidence/grade of recommendation added to the text. This enables readers to better understand the quality of the data forming the basis of the recommendations. RESULTS: A full version is available at the EAU Office or at . Systemic prostate biopsies under ultrasound guidance is the preferred diagnostic method and the use of periprostatic injection of a local anaesthetic can significantly reduce pain/discomfort associated with the procedure. Active treatment (surgery or radiation) is mostly recommended for patients with localized disease and a long life expectancy with radical prostatectomy being the only treatment evaluated in a randomized controlled trial. Follow-up is at large based on prostate specific antigen (PSA) and a disease-specific history with imaging only indicated when symptoms occur. Cytotoxic therapy has become an option for selected patients with hormone refractory prostate cancer. CONCLUSION: The knowledge in the field of prostate cancer is rapidly changing. These EAU guidelines on prostate cancer summarize the most recent findings and put them into clinical practice.

Starreveld JS, Wolters RJ, Romeijnders AC, Pijnenborg L, Goudswaard AN. · Nederlands Huisartsen Genootschap, afd. Richtlijnontwikkeling en Wetenschapsbeleid, Postbus 3231, 3502 GE Utrecht. · Ned Tijdschr Geneeskd. · Pubmed #16038160 No free full text.

Abstract: The 1997 practice guideline from the Dutch College of General Practitioners concerning lower urinary-tract symptoms (LUTS) in middle-aged and elderly men has been revised and some points have been adapted. The underlying cause of LUTS in middle-aged and elderly men is an improperly functioning voiding mechanism of the bladder associated with ageing. Symptoms are not simply due to prostate enlargement. In uncomplicated LUTS the patient's perception of the level of inconvenience is very important in considering and choosing therapeutic options. Percussion of the bladder after micturition is no longer universally advised. In general, invasive treatment is more effective in relieving symptoms than medical treatment, although invasive treatment causes more adverse effects. LUTS and prostate cancer are different entities, and LUTS is not a risk factor for prostate cancer. The issue of prostate cancer is discussed in this practice guideline in order to clear up popular misconceptions and to enhance the practical implementation of this guideline.

Bruyère F, Traxer O. · Service d'urologie, CHU Bretonneau, 2, Boulevard Tonnelle, 37044 Tours, France. · Ann Urol (Paris). · Pubmed #16008113 No free full text.

Abstract: Prostate cancer was the subject of communications, round tables and plenary sessions at the 98th congress of the Association française d'urologie (AFU). We report the whole of the meetings on the subject by classifying them by categories: epidemiology and biological diagnosis, information to patients included in screening (recommendations of the ANAES), biopsies and IRM, radiotherapy, radical prostatectomy, brachytherapy, HIFU (High Intensity Focused Ultrasound), functional consequences and quality of life, treatment of PSA elevation, advanced cancer of the prostate, place of surgery in T3 cancers of the prostate, research.

Kataja VV, Bergh J. · Invited author and member of the task force, University Hospital of Kuopio, POB 1777, FIN-70 211 Kuopio, Finland. · Ann Oncol. · Pubmed #15888746 links to  free full text

This publication has no abstract.

Walsh PC. · No affiliation provided · J Urol. · Pubmed #15879791 No free full text.

This publication has no abstract.

Soulié M, Barré C, Beuzeboc P, Chautard D, Cornud F, Eschwege P, Fontaine E, Molinié V, Moreau JL, Péneau M, Ravery V, Rébillard X, Richaud P, Ruffion A, Salomon L, Staerman F, Villers A, Anonymous00315. · No affiliation provided · Prog Urol. · Pubmed #15779654 No free full text.

This publication has no abstract.